Vulvar and Vaginal Atrophy in Postmenopausal Women: Findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) Survey

2013 ◽  
Vol 10 (7) ◽  
pp. 1790-1799 ◽  
Author(s):  
Sheryl A. Kingsberg ◽  
Susan Wysocki ◽  
Leslie Magnus ◽  
Michael L. Krychman
Keyword(s):  
Postmenopausal Women ◽  
Treatment Options ◽  
Vaginal Atrophy ◽  
Women’S Views

scholarly journals Management of Vaginal Atrophy: Implications from the REVIVE Survey

2014 ◽  
Vol 8 ◽  
pp. CMRH.S14498 ◽  
Author(s):  
Susan Wysocki ◽  
Sheryl Kingsberg ◽  
Michael Krychman
Keyword(s):  
Unmet Needs ◽  
Medical Condition ◽  
Treatment Options ◽  
Healthcare Providers ◽  
Treatment Preferences ◽  
Vaginal Atrophy ◽  
Vaginal Symptoms ◽  
Poor Understanding ◽  
Women’S Views

Vulvar and vaginal atrophy (VVA) is a chronic and progressive medical condition common in postmenopausal women. Symptoms of VVA such as dyspareunia, vaginal dryness, irritation, and itching can negatively impact sexual function and quality of life. The REVIVE (REal Women's Views of Treatment Options for Menopausal Vaginal ChangEs) survey assessed knowledge about VVA and recorded attitudes about interactions with healthcare providers (HCPs) and available treatment options for VVA. The REVIVE survey identified unmet needs of women with VVA symptoms such as poor understanding of the condition, poor communication with HCPs despite the presence of vaginal symptoms, and concerns about the safety, convenience, and efficacy of available VVA treatments. HCPs can address these unmet needs by proactively identifying patients with VVA and educating them about the condition as well as discussing treatment preferences and available therapies for VVA.

Oxytocin stimulates cell proliferation in vaginal cell line Vk2E6E7

2017 ◽  
Vol 23 (1) ◽  
pp. 6-12 ◽  
Author(s):  
Theodora K Kallak ◽  
Kerstin Uvnäs-Moberg
Keyword(s):  
Cell Proliferation ◽  
Postmenopausal Women ◽  
Cell Line ◽  
Colorimetric Assay ◽  
Treatment Options ◽  
Oxytocin Receptor ◽  
Immunofluorescent Staining ◽  
Vaginal Atrophy ◽  
Caveolin 1

Objective During and after menopause, the symptoms of vaginal atrophy cause great discomfort and necessitate effective treatment options. Currently, vaginally applied oxytocin is being investigated as a treatment for the symptoms of vaginal atrophy in postmenopausal women. To clarify the mechanisms behind oxytocins effects on vaginal atrophy, the present study investigated the effects of oxytocin on cell proliferation in the cells of the Vk2E6E7 line, a non-tumour vaginal cell line. The study also compared the effects of oxytocin with those of estradiol (E2). Study design The effects of both oxytocin and E2 on the proliferation of Vk2E6E7 cells were investigated using Cell Proliferation ELISA BrdU Colorimetric Assay. The expression of both oxytocin and oxytocin receptor was studied in Vk2E6E7 cells using quantitative real-time polymerase chain reaction and immunofluorescent staining. Main outcome measures Cell proliferation and gene expression. Results Oxytocin increased cell proliferation both time dependently and dose dependently. This differed from the effect pattern observed in cells treated with E2. In addition, in oxytocin-treated cells, the oxytocin receptor was found to be co-localized with caveolin-1, indicating pro-proliferative signalling within the cell. Conclusions Oxytocin stimulates cell proliferation and the co-localization of oxytocin receptor with caveolin-1 in oxytocin-treated cells, supporting the role of oxytocin signalling in cell proliferation. In addition, these findings suggest that increased cell proliferation is one mechanism by which local vaginal oxytocin treatment increases vaginal thickness and relieves vaginal symptoms in postmenopausal women with vaginal atrophy.

VAGINAL METABOLITES IN POSTMENOPAUSAL WOMEN WITH OR WITHOUT VULVO-VAGINAL ATROPHY AT BASELINE AND AFTER OSPEMIFEME AND SYSTEMIC HORMONE TREATMENT

Maturitas ◽  
2021 ◽  
Author(s):  
Claudio Foschi ◽  
Stefania Alvisi ◽  
Maurizio Baldassarre ◽  
Luca Laghi ◽  
Giulia Gava ◽  
...  
Keyword(s):  
Postmenopausal Women ◽  
Hormone Treatment ◽  
Vaginal Atrophy

Vaginal microbiota, vulvar vaginal atrophy, and vaginal signs in postmenopausal women

Maturitas ◽  
2019 ◽  
Vol 124 ◽  
pp. 149
Author(s):  
Svetlana Yureneva ◽  
Yelena Yeprikyan ◽  
Andrey Donnikov ◽  
Larisa Ezhova ◽  
Dmitrij Trofimov
Keyword(s):  
Postmenopausal Women ◽  
Vaginal Microbiota ◽  
Vaginal Atrophy

Role of topical oxytocin in improving vaginal atrophy in postmenopausal women: a randomized, controlled trial

Climacteric ◽  
2018 ◽  
Vol 21 (2) ◽  
pp. 174-178 ◽  
Author(s):  
H. A. Torky ◽  
A. Taha ◽  
H. Marie ◽  
E. El-Desouky ◽  
O. Raslan ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Postmenopausal Women ◽  
Controlled Trial ◽  
Vaginal Atrophy ◽  
Randomized Controlled

scholarly journals The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Ilnaz Zohrabi ◽  
Parvin Abedi ◽  
Somayeh Ansari ◽  
Elham Maraghi ◽  
Nader Shakiba Maram ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Postmenopausal Women ◽  
Controlled Trial ◽  
Vaginal Atrophy ◽  
Randomized Controlled ◽  
Vaginal Gel

Management of Postmenopausal Vaginal Atrophy: Review of Literature

2017 ◽  
Vol 5 (1) ◽  
pp. 51-57
Author(s):  
Meena Dayal ◽  
Preeti Yadav
Keyword(s):  
Quality Of Life ◽  
Postmenopausal Women ◽  
Clinical Significance ◽  
South Asian ◽  
Cost Effective ◽  
Vaginal Atrophy ◽  
Review Of Literature ◽  
Urogenital Atrophy ◽  
Effective Analysis

ABSTRACT Aim As there is dilemma for treatment of postmenopausal vaginal atrophy, effort has been made to review the literature for the same. Background About half of all postmenopausal women will experience symptoms related to urogenital atrophy. Vaginal atrophy becomes clinically apparent 4 to 5 years after menopause, and subjective complaints as well as objective changes are present in 25 to 50% of all postmenopausal women. Review results Measures could be taken for not only treatment but also prevention of atrophy before symptoms become troublesome, but establishment of this prevention principle globally would require a formal cost-effective analysis and further research. Conclusion Treatment with local estrogen is simple, safe, and can transform a woman’s quality of life. Clinical significance Women experiencing sexual and urinary symptoms as a consequence of vaginal atrophy should be diagnosed and treated without delay in order to avoid a cascade of events which do not resolve spontaneously. How to cite this article Yadav P, Dayal M. Management of Postmenopausal Vaginal Atrophy: Review of Literature. J South Asian Feder Menopause Soc 2017;5(1):51-57.

Sign in / Sign up

Export Citation Format

Share Document